Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternative

被引：0
|
作者：
Hammoudi, N. [1 ]
Hassid, D. [1 ]
Bonnet, J. [1 ]
Minh, M. L. Tran [1 ]
Baudry, C. [1 ]
Chedouba, L. [1 ]
Vauthier, A. [1 ]
Gornet, J. M. [1 ]
Allez, M. [1 ]
机构：
[1] APHP St Louis, Gastroenterol, Paris, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P515
引用
收藏
页码：643 / 643
页数：1
相关论文
共 50 条
  • [31] Infliximab infusion time in patients with inflammatory bowel diseases: Is longer really safer?
    Belhassan, Mehdi
    Zeitoun, Jean-David
    Lefevre, Jeremie H.
    Charachon, Antoine
    Amiot, Aurelien
    Le Baleur, Yann
    Sobhani, Iradj
    Delchier, Jean-Charles
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (02) : 189 - 192
  • [32] Infliximab in pediatric inflammatory bowel diseases: the Geneva experience
    Mueller, P.
    Rivier, A. Giroud
    Tempia-Schaeppi, M.
    Belli, D. C.
    SWISS MEDICAL WEEKLY, 2008, 138 : 41S - 41S
  • [33] Azathioprine in inflammatory bowel disease, a safe alternative?
    Tanis, AA
    MEDIATORS OF INFLAMMATION, 1998, 7 (03) : 141 - 144
  • [34] Infliximab and amyloidosis secondary to inflammatory bowel diseases - Reply
    Casellas, F
    MEDICINA CLINICA, 2005, 124 (19): : 758 - 758
  • [35] Predictive Factors of Response to Infliximab in Inflammatory Bowel Diseases
    Bourrier, Anne
    Seksik, Philippe
    Sokol, Harry
    Johanet, Catherine
    Nion-Larmurier, Isabelle
    Beaugerie, Laurent
    Cosnes, Jacques
    GASTROENTEROLOGY, 2010, 138 (05) : S688 - S688
  • [36] Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
    Nicolas Williet
    Stephane Paul
    Laurent Peyrin-Biroulet
    Xavier Roblin
    Digestive Diseases and Sciences, 2016, 61 : 990 - 995
  • [37] Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
    Williet, Nicolas
    Paul, Stephane
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (04) : 990 - 995
  • [38] Therapeutic innovations in inflammatory bowel diseases
    Vanhove, W.
    Nys, K.
    Vermeire, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (01) : 49 - 58
  • [39] Rapid desensitization for the management of hypersensitivity reaction to biologicals-Infliximab and adalimumab in inflammatory bowel disease patients
    Novotna, B.
    Prochazkova, L.
    Zboril, V
    Prokopova, L.
    Smerkova, H.
    ALLERGY, 2017, 72 : 223 - 224
  • [40] Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease
    Rosh J.R.
    Current Gastroenterology Reports, 2008, 10 (3) : 302 - 307
12345